Abivax (ABX) Demonstrates Safety of Obefazimod and Experiences a 38% Stock Surge in One Day Following Positive Phase 3 Clinical Trial Results
1. Stock Price Soars as Safety Concerns are Addressed
French biotech company Abivax (ticker: ABX) announced additional data from its Phase 3 clinical trial of obefazimod, a candidate drug for the treatment of Ulcerative Colitis, which addressed safety concerns. Following the announcement, Abivax's stock price surged 38% to $132.89 on the New York Stock Exchange, recovering from previous declines. The market had been concerned about cases of cancer reported in the high-dose group, but this announcement confirmed that these concerns were unfounded. In the biopharma sector, even if initial efficacy data is promising, companies must address potential side effects to fully realize their value.
2. Cumulative Exposure Data Confirms Safety
Abivax's additional safety data reflects a more precise assessment of the risks associated with long-term obefazimod use, as cumulative exposure time increases. The results of a supplemental cohort analysis from the Phase 3 trial showed that the incidence of Non-Melanoma Skin Cancer (NMSC) and other cancers was within the natural background range for patients with Ulcerative Colitis. In particular, patients who developed cancer were elderly or had clear risk factors, such as a history of thienopyridine use. Therefore, the drug itself is considered to have a very low causal relationship with cancer, which further increases the likelihood of approval.
3. Promising Efficacy Reconfirmed and Dosage Strategy Clarified
This Phase 3 trial (ABTECT) Maintenance Part 2 also reconfirmed the excellent efficacy of obefazimod. In patients who had not responded to or relapsed after previous treatments, increasing the dose of obefazimod to 50mg resulted in 45.5% of patients achieving clinical remission. In addition, endoscopic remission was achieved in 34.5% of patients, and overall clinical response was 61.5%, demonstrating high therapeutic efficacy. This provides a new, stepped-dose treatment guideline for patients who are resistant to drugs, which has significant medical implications.
4. Competitiveness in the $10 Billion Autoimmune Market
The global Ulcerative Colitis market is projected to grow rapidly from approximately $10.4 billion in 2025 to $21 billion in 2034, making it a high-value market. Currently, injectable biologics such as Stelara from Johnson & Johnson and Skyrizi from AbbVie, as well as oral JAK inhibitors, are in fierce competition. Obefazimod is the first oral drug that targets microRNA-124 (miR-124) and offers unique convenience. With the resolution of cancer concerns, its safety profile has been significantly strengthened, allowing it to compete with major pharmaceutical companies.
5. Approval Timeline and Global Big Pharma M&A Prospects
Abivax plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the fourth quarter of this year, as planned, and will announce the results of a Phase 2b clinical trial for Crohn's disease in mid-2027. Obefazimod has been recognized as having the potential to be a mega-blockbuster drug, and has been considered as a potential acquisition target by major pharmaceutical companies such as AstraZeneca and Eli Lilly, with a potential deal size of up to $18 billion. With the confirmation of 48-week long-term safety, Abivax's position in global partnership negotiations has been further strengthened. This clinical success will be an important turning point in changing the long-term trend of the autoimmune disease market.
Abivax's recent announcement of additional Phase 3 clinical data for obefazimod has significantly reduced regulatory uncertainty by demonstrating that the previously concerning risk of cancer (including NMSC) with high-dose administration is within the normal range for patients with Ulcerative Colitis. From an investor perspective, this strengthens the credibility of the timeline for the planned submission of a New Drug Application (NDA) to the U.S. FDA in the fourth quarter of 2026, and preserves its commercial value as a potential M&A candidate valued at $18 billion. From a research and medical perspective, the study presents a significant scientific achievement by providing a new treatment protocol for refractory patients who have failed to respond to existing biologic therapies, achieving a 45.5% clinical remission rate with a 50mg dose increase. In the long term, as a unique oral miR-124 targeted drug that can compete with Johnson & Johnson's Stelara and AbbVie's Skyrizi in the $10.4 billion global Ulcerative Colitis market, it has the potential to become a game-changer that can reshape the market.